Weight Loss

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH),...

Eli Lilly and Co. (NYSE:LLY) is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion. Expectations are slightly higher for the quarter, primarily driven by the...

Novo Nordisk A/S (NYSE:NVO) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg). The submission is based on clinical data from the STEP UP and STEP UP...

WW International, Inc. (WeightWatchers) (NASDAQ:WW) announced on Tuesday the successful completion of its strategic reorganization process. WeightWatchers implemented a financial reorganization transaction in May to strengthen its financial position and increase investment flexibility. The...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early...

Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections. Yellow Card...

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatment. While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are...

Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Novo Nordisk A/S (NYSE:NVO) has reportedly launched its weight-loss drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:LLY). In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the...

Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment. What To Know: The therapy, a long-acting, peptide-antibody conjugate administered...

On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S‘ (NYSE:NVO) phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes...

Eli Lilly And Co (NYSE:LLY) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The company released its topline data from the trial in April. At 40...

A surge in demand for weight-loss and diabetes medications, paired with fears of incoming tariffs, has propelled Ireland to the center of a pharmaceutical trade boom with the U.S., dramatically widening the bilateral trade imbalance. This year alone, $36 billion worth of hormone ingredients—...